Literature DB >> 21232153

The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations.

Lynn Htet Htet Aung1, Rui-Xing Yin, Lin Miao, Xi-Jiang Hu, Ting-Ting Yan, Xiao-Li Cao, Dong-Feng Wu, Qing Li, Shang-Ling Pan, Jin-Zhen Wu.   

Abstract

BACKGROUND: Proprotein convertase subtilisin-like kexin type 9 (PCSK9) plays a key role in regulating plasma low-density lipoprotein cholesterol (LDL-C) levels. However, the association of E670G (rs505151) polymorphism in the PCSK9 gene and serum lipid levels is inconsistent in several previous studies. The present study was undertaken to detect the association of PCSK9 E670G polymorphism and several environmental factors with serum lipid levels in the Guangxi Bai Ku Yao and Han populations.
METHODS: A total of 649 subjects of Bai Ku Yao and 646 participants of Han were randomly selected from our previous samples. Genotypes of the PCSK9 E670G polymorphism were determined via polymerase chain reaction and restriction fragment length polymorphism combined with gel electrophoresis, and then confirmed by direct sequencing.
RESULTS: Serum levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), LDL-C, and apolipoprotein (Apo) AI were lower in Bai Ku Yao than in Han (P < 0.01 for all). The frequency of G allele was 2.00% in Bai Ku Yao and 4.80% in Han (P < 0.01). There was significant difference in the genotypic and allelic frequencies between Bai Ku Yao and Han (P < 0.01); between normal LDL-C (≤ 3.20 mmol/L) and high LDL-C subgroups (> 3.20 mmol/L, P < 0.01) in Bai Ku Yao; and between normal HDL-C (≥ 0.91 mmol/L) and low HDL-C (< 0.91 mmol/L, P < 0.05), between normal ApoAI (≥ 1.00 g/L) and low ApoAI (< 1.00 g/L, P < 0.05), or between normal ApoAI/ApoB ratio (≥ 1.00) and low ApoAI/ApoB ratio (< 1.00, P < 0.01) subgroups in Han. The G allele carriers in Han had higher serum HDL-C levels and the ratio of ApoAI to ApoB than the G allele noncarriers. The G allele carriers in Han had higher serum HDL-C and ApoAI levels than the G allele noncarriers in males (P < 0.05 for each), whereas the G allele carriers had lower serum ApoB levels and higher the ratio of ApoAI to ApoB than the G allele noncarriers in females (P < 0.05 for all). Serum HDL-C and ApoAI levels in Han were correlated with genotypes (P < 0.05) in males, and serum ApoB levels and the ratio of ApoAI to ApoB were associated with genotypes (P < 0.05) in females.
CONCLUSIONS: The PCSK9 E670G polymorphism is mainly associated with some serum lipid parameters in the Han population. The G allele carriers had higher serum HDL-C and ApoAI levels in males, and lower serum ApoB levels and higher the ApoAI/ApoB ratio in females than the G allele noncarriers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21232153      PMCID: PMC3035481          DOI: 10.1186/1476-511X-10-5

Source DB:  PubMed          Journal:  Lipids Health Dis        ISSN: 1476-511X            Impact factor:   3.876


Introduction

Abnormalities in lipid metabolism such as elevated serum levels of total cholesterol (TC) [1], triglyceride (TG) [2], low-density lipoprotein cholesterol (LDL-C) [3], and apolipoprotein (Apo) B [4], or low levels of high-density lipoprotein cholesterol (HDL-C) and ApoAI [4-6] are considered as major risk factors for coronary artery disease (CAD). It is generally agreed that dyslipidemia is complex and the result of the interactions [7,8] of multiple genes [9-11] and multiple environmental factors [12,13]. Both family and twin studies have consistently shown that 40-60% of the interindividual variation in plasma lipid phenotypes is genetic in etiology [14-16]. Although multiple genetic defects have been identified that cause rare Mendelian forms of severe hypercholesterolemia or hypocholesterolemia, the sequence variations in the genome accounting for most of the variation in serum lipid levels in the general population have not been determined. Proprotein convertase subtilisin-like kexin type 9 (PCSK9, OMIM 607786) is a newly discovered serine protease that plays a key role in LDL-C homeostasis by mediating LDL receptor (LDLR) breakdown through a post-transcriptional mechanism [17-20]. PCSK9 may also regulate ApoB-containing lipoprotein production and ApoB secretion [21,22], and promote production of nascent very low-density lipoprotein (VLDL) in the fasting state [23]. Human PCSK9 gene is approximately 22 kb long, comprising the promoter region and 12 exons, and it is located on chromosome 1p32. The gene produces a mRNA of 3636 bp encoding a 692-amino acid glycoprotein. This protein, also called neural apoptosis regulated convertase, is a serine protease belonging to the protease K subfamily of subtilases. It is a subfamily of proteases largely involved in the processing of inactive precursor proteins to the active product and seems to be involved in the inactivation and degradation of LDLR [24-26]. PCSK9 contains a signal sequence and prodomain at its N-terminus, followed by a catalytic domain and cysteine-rich carboxy-terminal domain. PCSK9 undergoes autocatalytic cleavage in the endoplasmic reticulum, releasing the aminoterminal prodomain. The prodomain remains associated with the processed form of PCSK9 as it transits through the secretory pathway. Adenoviral-mediated over-expression of human PCSK9 in mice promotes the accumulation of LDL-C in the plasma but this response is absent in LDLR-deficient animals [18,20,27]. Recent studies show that PCSK9 binds directly to the extracellular domain of the LDLR [28,29] and increases its degradation [28]. PCSK9 is expressed most abundantly in the liver, kidney, and small intestine [30]. PCSK9 may enhance degradation of other receptor types or proteins during the development of cerebellum and telencephalon [30] and promote cerebellar cortical neurogenesis, possibly by increased recruitment of undifferentiated neural progenitor cells into the neuronal lineage [31]. The characterization of 'gain-of-function' versus 'loss-of-function' alleles of PCSK9 is based on the phenotype (LDL-C), and not on defined biochemical alterations. Several studies have found that missense mutations increasing the activity of PCSK9 (i.e., gain-of-function mutations) result in an increase of LDL-C levels and CAD [22,32-34] whereas nonsense mutations reducing PCSK9 activity (i.e., loss-of-function mutations) have the opposite effect, lowering LDL-C levels and reducing risk of CAD [35-37]. These findings reveal that PCSK9 activity is a major determinant of plasma levels of LDL-C in humans and make it an attractive therapeutic target for LDL-C lowering. Among the genetic variants of the PCSK9 gene, a common single nucleotide polymorphism (SNP), E670G (rs505151), in exon 12 deserved greater scrutiny, as it was responsible for an amino acid change that could potentially be associated with altered PCSK9 activity. The E670G polymorphism in humans has been found to be associated with modifications of serum LDL-C levels in some studies [38-42] but not in others [37,43-45]. China is a multiethnic country. There are 56 ethnic groups. Han is the largest ethnic group and Yao is the eleventh largest minority among the 55 minority groups according to the population size. There is also an isolated branch of the Yao minority, Bai Ku Yao (White-trouser Yao, all of men wear white knee-length knickerbockers). The population size is about 30000. Because of isolation from the other ethnic groups, the special customs and cultures including their clothing, intra-ethnic marriages, ballad, funeral, bronze drum, spinning top, dietary habits, and corn wine and rum intakes are still completely preserved to the present day. Previous reports by our group have found that several serum lipid phenotypes were lower in Bai Ku Yao than in Han Chinese from the same villages [12,13]. This ethnic difference in serum lipid profiles is still not well known. We hypothesized that some genetic polymorphisms may be different between the two ethnic groups [7-11]. Thus, the aim of this study was to detect the association of PCSK9 E670G polymorphism and several environmental factors with serum lipid phenotypes in the Guangxi Bai Ku Yao and Han populations.

Materials and methods

Study population

The study population included 649 subjects of Bai Ku Yao who reside in Lihu and Baxu villages in Nandan County, Guangxi Zhuang Autonomous Region, People's Republic of China. They were randomly selected from our previous stratified randomized cluster samples [12,13]. The ages of the subjects ranged from 15 to 80 years, with an average age of 35.68 ± 13.69 years. There were 324 males (49.92%) and 325 females (50.08%). All subjects were rural agricultural workers. The subjects accounted for 2.16% of total Bai Ku Yao population. During the same period, a total of 646 people of Han Chinese who reside in the same villages were also randomly selected from our previous stratified randomized cluster samples [12,13]. The average age of the subjects was 36.59 ± 17.56 years (range 15 to 80). There were 320 men (49.54%) and 326 women (50.46%). All of them were also rural agricultural workers. All study subjects were essentially healthy and had no evidence of any chronic illness, including hepatic, renal, or thyroid. The participants with a history of heart attack or myocardial infarction, stroke, congestive heart failure, diabetes or fasting blood glucose ≥ 7.0 mmol/L determined by glucose meter were not included. The participants were not taking medications known to affect serum lipid levels (lipid-lowering drugs such as statins or fibrates, beta-blockers, diuretics, or hormones) at the time of sample extraction. The present study was approved by the Ethics Committee of the First Affiliated Hospital, Guangxi Medical University. Informed consent was obtained from all subjects after they received a full explanation of the study.

Epidemiological survey

The survey was carried out using internationally standardized methods, following a common protocol [46]. Demographic data, socioeconomic status, and lifestyle factors were collected with standardized questionnaires. The alcohol information included questions about the number of liangs (about 50 g) of rice wine, corn wine, rum, beer, or liquor consumed during the preceding 12 months. Alcohol consumption was categorized into groups of grams of alcohol per day: < 25 and ≥ 25. Smoking status was categorized into groups of cigarettes per day: < 20 and ≥ 20. At each examination, weight and height were measured with subjects in light clothing and without shoes. Body weight was measured to the nearest 50 grams, using a portable balance scale. Height was measured to the nearest 0.5 cm with a portable steel measuring device. Body mass index (BMI) was calculated as the weight in kilograms divided by the square of height in meters. Sitting blood pressure was measured three times with the use of a mercury sphygmomanometer after the subjects had a 5-minute rest, and the average of the three measurements was used for the level of blood pressure. Systolic blood pressure was determined by the first Korotkoff sound, and diastolic blood pressure by the fifth Korotkoff sound.

Biochemical measurements

Fasting venous blood samples (8 mL) were obtained from all participants between 8 and 11 AM. A part of the sample (3 mL) was collected into glass tubes and allowed to clot at room temperature, and used to determine serum lipid levels. Another part of the sample (5 mL) was transferred to tubes with anticoagulate solution (4.80 g/L citric acid, 14.70 g/L glucose, and 13.20 g/L tri-sodium citrate) and used to extract DNA. Immediately following clotting serum was separated by centrifugation for 15 minutes at 3000 rpm. The levels of TC, TG, HDL-C, and LDL-C in samples were measured using commercial enzymatic reagents, Tcho-1, TG-LH (RANDOX Laboratories Ltd., Ardmore, Diamond Road, Crumlin Co. Antrim, United Kingdom, BT29 4QY), Cholestest N HDL, and Cholestest LDL (Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan); respectively. Serum ApoAI and ApoB levels were detected by the immunoturbidimetric immunoassay using a commercial kit (RANDOX Laboratories Ltd.). All determinations were performed with an autoanalyzer (Type 7170A; Hitachi Ltd., Tokyo, Japan) in the Clinical Science Experiment Center of the First Affiliated Hospital, Guangxi Medical University [12,13].

DNA amplification and genotyping

Genomic DNA was isolated from peripheral blood leukocytes using the phenol-chloroform method as previously described [7-11]. The extracted DNA was maintained at 4°C until analysis. Genotyping of the PCSK9 E670G polymorphism was performed by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). PCR amplification was performed using 5'-CACGGTTGTGTCCCAAATGG-3' and 5'-GAGAGGGACAAGTCGGAACC-3' (Sangon, Shanghai, People's Republic of China) as the forward and reverse primer pairs; respectively. Each amplification reaction was performed using 100 ng of genomic DNA in 25 μL of reaction mixture consisting of 25 μmol/L of each primer, 200 μmol/L of each deoxynucleotide triphoisphate, 2.5 μL of 10 × PCR buffer (100 mM Tris-HCl, pH 8.3, 500 mM KCl, 20 mM MgCl2, 1% Triton), and 2 units of Taq polymerase. After initial denaturizing at 94°C for 5 min, the reaction mixture was subjected to 35 cycles of 30 s denaturation at 94°C, 30 s annealing at 58°C and extension 30 s at 72°C, followed by a final 5 min extension at 72°C. After electrophoresis on a 1.2% agarose gel with 0.5 μg/mL ethidium bromide (EB), the amplification products were visualized under ultraviolet light. Then 2 U of Eam 1104I restriction enzyme was added directly to the PCR products (10 μL) and digested at 37°C overnight. After restriction enzyme digestion of the amplified DNA, the genotypes were identified by electrophoresis on 2% agagarose gels and visualized with ethidium-bromide staining ultraviolet illumination. Genotypes were scored by an experienced reader blinded to epidemiological data and serum lipid levels. Six samples (AA, AG and GG genotypes in two; respectively) detected by the PCR-RFLP were also confirmed by direct sequencing. The PCR products were purified by low melting point gel electrophoresis and phenol extraction, and then the DNA sequences were analyzed in Shanghai Sangon Biological Engineering Technology & Services Co., Ltd., People's Republic of China.

Diagnostic criteria

The normal values of serum TC, TG, HDL-C, LDL-C, ApoAI, ApoB levels, and the ratio of ApoAI to ApoB in our Clinical Science Experiment Center were 3.10-5.17, 0.56-1.70, 0.91-1.81, 2.70-3.20 mmol/L, 1.00-1.78, 0.63-1.14 g/L, and 1.00-2.50; respectively. The individuals with TC > 5.17 mmol/L and/or TG > 1.70 mmol/L were defined as hyperlipidemic [12,13]. Hypertension was diagnosed according to the criteria of 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension [47,48]. The diagnostic criteria of overweight and obesity were according to the Cooperative Meta-analysis Group of China Obesity Task Force. Normal weight, overweight and obesity were defined as a BMI < 24, 24-28, and > 28 kg/m2; respectively [49].

Statistical analyses

Epidemiological data were recorded on a pre-designed form and managed with Excel software. Data analysis was performed using the statistical software package SPSS 13.0 (SPSS Inc., Chicago, Illinois). Quantitative variables were expressed as mean ± standard deviation (serum TG levels were presented as medians and interquartile ranges). Qualitative variables were expressed as percentages. Allele frequency was determined via direct counting, and the standard goodness-of-fit test was used to test the Hardy-Weinberg equilibrium. Difference in genotype distribution between the groups was obtained using the chi-square test. The difference in general characteristics between Bai Ku Yao and Han was tested by the Student's unpaired t-test. The association of genotypes and serum lipid parameters was tested by analysis of covariance (ANCOVA). Sex, age, BMI, blood pressure, alcohol consumption, cigarette smoking were adjusted for the statistical analysis. In order to assess the association of serum lipid levels with genotypes (AA = 1, AG/GG = 2) and several environment factors, multiple linear regression analysis with stepwise modeling was also performed in the combined population of Bai Ku Yao and Han, Bai Ku Yao, Han, males and females; respectively. A P value of less than 0.05 was considered statistically significant.

Results

General characteristics and serum lipid levels

The general characteristics and serum lipid levels between the Bai Ku Yao and Han populations are presented in Table 1. The levels of height, weight, systolic blood pressure, pulse pressure, serum TC, HDL-C, LDL-C, ApoAI were lower in Bai Ku Yao than in Han Chinese (P < 0.01-0.001), whereas the percentage of subjects who consumed alcohol was higher in Bai Ku Yao than in Han (P < 0.001). There were no significant differences in the levels of BMI, diastolic blood pressure, serum TG, ApoB, the ratio of ApoAI to ApoB, age structure, the percentage of subjects who smoked cigarettes, or the ratio of male to female between the two ethnic groups (P > 0.05 for all).
Table 1

Comparison of demographic, lifestyle characteristics and serum lipid levels between Bai Ku Yao and Han Chinese

CharacteristicBai Ku YaoHan Chineset (χ2)P
Number649646--
Male/female324/325320/3260.1390.889
Age (years)35.68 ± 13.6936.59 ± 17.56-1.0400.298
Height (cm)153.27 ± 7.17156.89 ± 8.83-8.3560.000
Weight (kg)51.85 ± 6.9954.32 ± 10.32-5.0440.000
Body mass index (kg/m2)22.04 ± 2.2822.03 ± 3.650.0420.967
Systolic blood pressure (mmHg)116.48 ± 15.78119.54 ± 17.16-3.3390.001
Diastolic blood pressure (mmHg)74.81 ± 8.9975.34 ± 11.10-0.9360.350
Pulse pressure (mmHg)41.66 ± 11.6444.21 ± 11.9-3.8970.000
Cigarette smoking [n (%)]
 Nonsmoker442 (68.1)492 (76.2)
 < 20 cigarettes/day101 (15.6)46 (7.1)
 ≥ 20 cigarettes/day106 (2.3)108 (16.7)1.4680.142
Alcohol consumption [n (%)]
 Nondrinker383 (59.0)490 (75.9)
 < 25 g/day186 (28.7)112 (17.3)
 ≥ 25 g/day74 (11.4)44 (6.8)5.6530.000
Total cholesterol (mmol/L)4.23 ± 0.934.63 ± 1.076.3420.000
Triglyceride (mmol/L)0.99 (0.66)1.02 (0.74)-1.7160.086
HDL-C (mmol/L)1.64 ± 0.411.75 ± 0.47-4.6430.000
LDL-C (mmol/L)2.50 ± 0.762.65 ± 0.82-3.1550.002
Apolipoprotein (Apo) AI (g/L)1.28 ± 0.321.35 ± 0.31-3.8670.000
ApoB (g/L)0.83 ± 0.210.84 ± 0.24-1.0760.282
ApoAI/ApoB1.68 ± 0.781.72 ± 0.61-0.8990.369

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. The value of TG was presented as median (interquartile range). The difference between the two ethnic groups was determined by the Wilcoxon-Mann-Whitney test.

Comparison of demographic, lifestyle characteristics and serum lipid levels between Bai Ku Yao and Han Chinese HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. The value of TG was presented as median (interquartile range). The difference between the two ethnic groups was determined by the Wilcoxon-Mann-Whitney test.

Results of electrophoresis and genotyping

After the genomic DNA of the samples was amplified by PCR and imaged by 2% agarose gel electrophoresis, the purpose gene of 440 bp nucleotide sequences could be seen in all samples (Figure 1). The genotypes identified were named according to the presence or absence of the enzyme restriction sites, when an A to G transversion at 670 locus of the PCSK9 gene. The presence of the cutting site indicates the A allele, while its absence indicates the G allele (cannot be cut). Thus, the GG genotype is homozygote for the absence of the site (band at 440 bp), AG genotype is heterozygote for the absence and presence of the site (bands at 440-, 290- and 150-bp), and AA genotype is homozygote for the presence of the site (bands at 290- and 150-bp; Figure 2). The distribution of genotypes of the SNP followed the Hardy-Weinberg equilibrium.
Figure 1

Electrophoresis of PCR products of the samples. Lane M, 100 bp marker ladder; lanes 1-6, samples. The 440 bp bands are the target genes.

Figure 2

Genotyping of the PCSK9 E670G polymorphism. Lane M, 100 bp marker ladder; lanes 1 and 2, GG genotype (440 bp); lanes 3 and 4, AG genotype (440-, 290- and 150-bp); and lanes 5 and 6, AA genotype (290- and 150-bp).

Electrophoresis of PCR products of the samples. Lane M, 100 bp marker ladder; lanes 1-6, samples. The 440 bp bands are the target genes. Genotyping of the PCSK9 E670G polymorphism. Lane M, 100 bp marker ladder; lanes 1 and 2, GG genotype (440 bp); lanes 3 and 4, AG genotype (440-, 290- and 150-bp); and lanes 5 and 6, AA genotype (290- and 150-bp).

Genotypic and allelic frequencies

The genotypic and allelic frequencies of E670G polymorphism in the PCSK9 gene are shown in Table 2. The frequency of A and G alleles was 98.00% and 2.00% in Bai Ku Yao, and 95.20% and 4.80% in Han (P < 0.01); respectively. The frequency of AA, AG and GG genotypes was 95.99%, 4.01% and 0% in Bai Ku Yao, and 91.02%, 8.36% and 0.62% in Han (P < 0.01); respectively. There was also significant difference in the genotypic and allelic frequencies between normal LDL-C (≤ 3.20 mmol/L) and high LDL-C subgroups (> 3.20 mmol/L, P < 0.01) in Bai Ku Yao; and between normal HDL-C (≥ 0.91 mmol/L) and low HDL-C (< 0.91 mmol/L, P < 0.05), between normal ApoAI (≥ 1.00 g/L) and low ApoAI (< 1.00 g/L, P < 0.05), or between normal ApoAI/ApoB ratio (≥ 1.00) and low ApoAI/ApoB ratio (< 1.00, P < 0.01) subgroups in Han.
Table 2

Comparison of the genotypic and allelic frequencies of PCSK9 E670G polymorphism between Bai Ku Yao and Han Chinese [n (%)]

GroupnGenotypeAllele

AAAGGGAG
Bai Ku Yao649623 (95.99)26 (4.01)0 (0.00)1272 (98.00)26 (2.00)
Han Chinese646588 (91.02)54 (8.36)4 (0.62)1230 (95.20)62 (4.80)
χ2-14.80515.447
P-0.0010.001
Bai Ku Yao
 Male324309 (95.37)15 (4.63)0 (0.00)633 (97.69)15 (2.31)
 Female325314 (96.62)11 (3.38)0 (0.00)639 (98.92)11 (1.08)
χ2-0.6540.641
P-0.4190.423
 Normal TC549529 (96.40)20 (3.60)0 (0.00)1078 (98.18)20 (1.82)
 High TC10094 (94.00)6 (6.00)0 (0.00)194 (97.00)6 (3.00)
χ2-1.8741.197
P-0.1710.274
 Normal TG550526 (95.64)24 (4.36)0 (0.00)1076 (97.82)24 (2.18)
 High TG9997 (97.98)2 (2.02)0 (0.00)196 (98.99)2 (1.01)
χ2-1.1980.653
P-0.2740.419
 Normal HDL-C460444 (96.52)16 (3.48)0 (0.00)904 (92.27)16 (7.73)
 Low HDL-C189179 (94.71)10 (5.29)0 (0.00)368 (97.35)10 (2.65)
χ2-1.1451.121
P-0.2850.290
 Normal LDL-C488475 (97.34)13 (2.66)0 (0.00)963 (98.67)13 (1.33)
 High LDL-C161148 (91.93)13 (8.07)0 (0.00)309 (95.96)13 (4.04)
χ2-9.2169.027
P-0.0020.003
 Normal ApoAI546523 (95.79)23 (4.21)0 (0.00)1069 (97.89)23 (2.11)
 Low ApoAI103100 (97.09)3 (2.91)0 (0.00)203 (98.54)3 (1.46)
χ2-0.1180.115
P-0.7320.734
 Normal ApoB605581 (95.87)25 (4.13)0 (0.00)1187 (98.10)25 (1.90)
 High ApoB4342 (97.67)1 (2.33)0 (0.00)283 (98.26)5 (1.74)
χ2-0.3380.331
P-0.5610.565
 NormalApoAI/ApoB605583 (96.36)22 (3.64)0 (0.00)1188 (98.18)22 (1.82)
 Low ApoAI/ApoB9284 (91.30)8 (8.70)0 (0.00)84 (95.45)4 (4.55)
χ2-1.9131.874
P-0.1690.171
Han Chinese
 Male320288 (90.00)32 (10.00)0 (0.00)608 (95.00)32 (5.00)
 Female326300 (92.02)22 (6.75)4 (1.23)626 (96.01)26 (3.09)
χ2-6.0420.772
P-0.4920.380
 Normal TC486442 (90.95)40 (8.20)4 (0.85)928 (98.56)44 (1.44)
 High TC160146 (91.25)14 (8.75)0 (0.00)306 (95.63)14 (4.37)
χ2-1.3570.013
P-0.5070.909
 Normal TG530480 (90.57)46 (8.68)4 (0.75)1010 (95.28)50 (4.72)
 High TG116108 (93.11)8 (6.89)0 (0.00)224 (96.55)8 (3.45)
χ2-1.3050.715
P-0.5210.398
 Normal HDL-C410366 (89.27)42 (10.24)2 (0.49)776 (94.63)44 (4.37)
 Low HDL-C236222 (94.07)12 (5.08)2 (0.85)458 (97.03)14 (2.97)
χ2-4.2224.024
P-0.0390.045
 Normal LDL-C458416 (90.83)38 (8.30)4 (0.87)874 (95.41)42 (4.59)
 High LDL-C188172 (91.49)16 (8.51)0 (0.00)360 (95.75)16 (4.25)
χ2-1.6560.068
P-0.4370.795
 Normal ApoAI594546 (91.92)44 (7.41)4 (0.67)1136 (95.62)52 (4.38)
 Low ApoAI5242 (80.77)10 (19.23)0 (0.00)92 (90.38)10 (8.62)
χ2-8.9995.744
P-0.0110.017
 Normal ApoB580530 (91.38)46 (7.93)4 (0.69)1060 (95.34)100 (4.66)
 High ApoB6658 (87.88)8 (12.12)0 (0.00)124 (93.94)8 (6.06)
χ2-1.1781.014
P-0.4110.314
 NormalApoAI/ApoB624572 (91.67)48 (7.67)4 (0.64)1192 (95.51)56 (4.49)
 Low ApoAI/ApoB2216 (72.73)6 (27.27)0 (0.00)38 (86.36)6 (13.64)
χ2-10.7257.787
P-0.0050.005

Normal TC, TC ≤ 5.17 mmol/L, High TC, TC > 5.17 mmol/L; Normal TG, TG ≤ 1.70 mmol/L, High TG, TG > 1.70 mmol/L; Normal HDL-C, HDL-C ≥ 0.91 mmol/L, Low HDL-C, HDL-C < 0.91 mmol/L; Normal LDL-C, LDL-C ≤ 3.20 mmol/L, High LDL-C, LDL-C > 3.20 mmol/L; Normal ApoAI, ApoAI ≥ 1.00 g/L, Low ApoAI, ApoAI < 1.00 g/L; Normal ApoB, ApoB ≤ 1.14 g/L, High ApoB, ApoB > 1.14 g/L; Normal ApoAI/ApoB, ApoAI/ApoB ≥ 1.00, Low ApoA1/B, ApoAI/ApoB < 1.00.

Comparison of the genotypic and allelic frequencies of PCSK9 E670G polymorphism between Bai Ku Yao and Han Chinese [n (%)] Normal TC, TC ≤ 5.17 mmol/L, High TC, TC > 5.17 mmol/L; Normal TG, TG ≤ 1.70 mmol/L, High TG, TG > 1.70 mmol/L; Normal HDL-C, HDL-C ≥ 0.91 mmol/L, Low HDL-C, HDL-C < 0.91 mmol/L; Normal LDL-C, LDL-C ≤ 3.20 mmol/L, High LDL-C, LDL-C > 3.20 mmol/L; Normal ApoAI, ApoAI ≥ 1.00 g/L, Low ApoAI, ApoAI < 1.00 g/L; Normal ApoB, ApoB ≤ 1.14 g/L, High ApoB, ApoB > 1.14 g/L; Normal ApoAI/ApoB, ApoAI/ApoB ≥ 1.00, Low ApoA1/B, ApoAI/ApoB < 1.00.

Results of sequencing

The results were shown as AA, AG and GG genotypes by PCR-RFLP, the AA, AG and GG genotypes were also confirmed by sequencing (Figure 3); respectively.
Figure 3

A part of the nucleotide sequence of the PCSK9 E670G polymorphism. (A) AA genotype; (B) AG genotype; (C) GG genotype.

A part of the nucleotide sequence of the PCSK9 E670G polymorphism. (A) AA genotype; (B) AG genotype; (C) GG genotype.

Genotypes and serum lipid levels

As shown in Table 3, the levels of HDL-C and the ratio of ApoAI to ApoB in Han Chinese but not in Bai Ku Yao were different between the AA and AG/GG genotypes (P < 0.05 for each). The G allele carriers had higher serum HDL-C levels and the ratio of ApoAI to ApoB than the G allele noncarriers. When serum lipid parameters in Han were analyzed according to sex, the G allele carriers had higher serum HDL-C and ApoAI levels than the G allele noncarriers in males (P < 0.05 for each), whereas the G allele carriers had lower serum ApoB levels and higher the ratio of ApoAI to ApoB than the G allele noncarriers in females (P < 0.05 for all).
Table 3

Comparison of serum lipid levels among genotypes of Bai Ku Yao and Han Chinese

GenotypenTC (mmol/L)TG (mmol/L)HDL-C (mmol/L)LDL-C (mmol/L)ApoAI (g/L)ApoB (g/L)ApoAI/ApoB
Bai Ku Yao
 AA6234.27 ± 0.930.98(0.67)1.62 ± 0.402.51 ± 0.771.28 ± 0.310.83 ± 0.211.66 ± 0.74
 AG/GG264.34 ± 1.081.04(0.54)1.60 ± 0.442.58 ± 0.671.24 ± 0.350.83 ± 0.201.59 ± 0.61
F-0.6790.0891.3270.5830.0420.2520.279
P-0.4100.6420.2500.4450.8390.6160.597
 Male
  AA3094.31 ± 1.081.09(0.79)1.63 ± 0.452.49 ± 0.911.32 ± 0.370.82 ± 0.231.77 ± 0.94
  AG/GG154.46 ± 1.321.04(0.62)1.61 ± 0.462.61 ± 0.721.26 ± 0.340.81 ± 0.221.68 ± 0.68
  F-0.7420.3300.2960.7920.0170.0030.003
  P-0.3900.7140.5870.3740.8970.9580.954
 Female
  AA3144.23 ± 0.760.91(0.59)1.62 ± 0.352.54 ± 0.791.23 ± 0.240.83 ± 0.191.56 ± 0.47
  AG/GG114.23 ± 0.861.05(0.51)1.60 ± 0.442.55 ± 0.901.23 ± 0.380.85 ± 0.181.52 ± 0.56
  F-0.0180.3900.1810.0030.0570.2210.217
  P-0.8950.6960.6710.9540.8110.6390.641
Han Chinese
 AA5884.61 ± 1.081.01(0.77)1.74 ± 0.472.63 ± 0.821.35 ± 0.310.84 ± 0.231.70 ± 0.59
 AG/GG584.79 ± 0.911.10(0.66)1.86 ± 0.552.74 ± 0.801.41 ± 0.330.83 ± 0.261.87 ± 0.77
F-0.6070.0893.9590.3322.1650.6505.394
P-0.4360.9290.0470.5650.1420.4200.021
 Male
  AA2884.53 ± 1.071.08(0.90)1.66 ± 0.432.58 ± 0.821.30 ± 0.290.83 ± 0.241.68 ± 0.65
  AG/GG325.13 ± 0.791.13(0.80)1.86 ± 0.572.98 ± 0.651.47 ± 0.330.94 ± 0.251.74 ± 0.82
  F-2.6540.7134.3652.0754.8251.4640.191
  P-0.1040.4760.0370.1510.0290.2270.663
 Female
  AA3004.69 ± 1.070.96(0.68)1.82 ± 0.482.71 ± 0.821.39 ± 0.320.85 ± 0.221.72 ± 0.53
  AG/GG264.51 ± 0.920.97(0.57)1.87 ± 0.542.56 ± 0.861.36 ± 0.310.74 ± 0.231.97 ± 0.72
  F-0.1380.1901.2350.1780.1304.4126.655
  P-0.7100.8500.2670.6740.7190.0360.010

TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B; ApoAI/ApoB, the ratio of apolipoprotein AI to apolipoprotein B. The value of TG was presented as median (interquartile range). The difference between the genotypes was determined by the Wilcoxon-Mann-Whitney test.

Comparison of serum lipid levels among genotypes of Bai Ku Yao and Han Chinese TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B; ApoAI/ApoB, the ratio of apolipoprotein AI to apolipoprotein B. The value of TG was presented as median (interquartile range). The difference between the genotypes was determined by the Wilcoxon-Mann-Whitney test.

Relative factors for serum lipid parameters

Multiple linear regression analysis showed that serum HDL-C levels were correlated with genotypes in Han (P < 0.05) but not in Bai Ku Yao (Table 4). When multiple linear regression analysis was performed in the males and females in both ethnic groups; respectively, we showed that serum HDL-C and ApoAI levels in Han but not in Bai Ku Yao were correlated with genotypes (P < 0.05) in males, and serum ApoB levels and the ratio of ApoAI to ApoB were associated with genotypes (P < 0.05, Table 5) in females. Serum lipid parameters were also correlated with sex, age, BMI, alcohol consumption, cigarette smoking, and blood pressure in both ethnic groups (P < 0.05-0.001, Tables 4 and 5).
Table 4

Correlative factors for serum lipid parameters between Bai Ku Yao and Han Chinese

Lipid parameterRelative factorUnstandardized coefficientStd. errorStandardized coefficienttP
Bai plus Han
 TCDiastolic blood pressure0.0200.0030.2057.0260.000
Body mass index0.0600.0090.1906.8120.000
Age0.1080.0170.1806.5440.000
Sex0.1150.0530.0582.1710.030
Ethnic group-0.3320.052-0.163-6.3550.000
 TGBody mass index0.0630.0110.1625.5990.000
Sex-0.2360.073-0.097-3.2080.001
Alcohol consumption0.1460.0470.0943.1290.002
Ethnic group-0.1440.065-0.060-2.2170.027
 HDL-CAge0.0640.0080.2378.1870.000
Ethnic group-0.1280.024-0.144-5.2950.000
Body mass index-0.0190.004-0.132-4.5610.000
Sex0.1370.0270.1555.1010.000
Alcohol consumption0.0770.0170.1364.4630.000
Genotype0.1260.0490.0692.5540.011
Diastolic blood pressure0.0030.0010.0662.1890.029
 LDL-CBody mass index0.0550.0070.2268.0420.000
Age0.0790.0130.1716.0870.000
Diastolic blood pressure0.0110.0020.1495.1380.000
Alcohol consumption-0.1320.026-0.136-4.9780.000
Ethnic group-0.1070.042-0.067-2.5280.012
 ApoAIAge0.0500.0060.2678.8140.000
Alcohol consumption0.0740.0120.1866.2730.000
Sex0.0560.0180.0913.0930.002
Ethnic group-0.0780.0170.123-4.6510.000
Diastolic blood pressure0.0010.0010.0792.6290.009
 ApoBBody mass index0.0170.0020.2438.7160.000
Systolic Blood pressure0.0040.0010.1766.0410.000
Age0.0200.0040.1485.3920.000
Bai Ku Yao
 TCBody mass index0.0760.0140.2115.2730.000
Sex0.0810.0240.1403.4310.000
Systolic blood pressure0.0080.0040.0882.1390.033
 TGSex-0.4780.118-0.211-4.0600.001
Body mass index0.0690.0200.1413.4980.001
Alcohol consumption0.1760.0630.1332.8160.005
Cigarette smoking-0.1790.073-0.128-2.4550.014
 HDL-CAge0.0520.0110.1924.6220.000
Alcohol consumption0.0770.0220.1693.5800.000
Sex0.0710.0360.0911.9980.046
 LDL-CBody mass index0.0660.0120.2235.5600.000
Sex0.0640.0200.1373.2640.001
Alcohol consumption-0.1070.033-0.135-3.2720.001
Diastolic blood pressure0.0070.0030.0912.1920.029
 ApoAIAlcohol consumption0.0900.0140.2536.3130.000
Age0.0400.0080.1924.7830.000
 ApoBBody mass index0.0190.0040.2175.3740.000
Age0.0170.0060.1172.7720.006
Diastolic blood pressure0.0020.0010.0952.2860.023
Alcohol consumption-0.0230.010-0.094-2.2660.024
 ApoAI/ApoBSex-0.2340.060-0.150-3.9030.000
Body mass index-0.0420.013-0.122-3.1430.002
Age0.0570.0210.1062.7380.006
Han Chinese
 TCDiastolic blood pressure0.0280.0040.2837.0420.000
Age0.1110.0220.1864.950.000
Body mass index0.0500.0110.1724.4640.000
Sex0.3540.0880.1654.0220.000
Cigarette smoking0.1100.0530.0862.0820.038
 TGDiastolic blood pressure0.0200.0050.1764.1740.000
Body mass index0.0590.0140.1714.1810.000
Cigarette smoking0.1480.0630.0972.3570.019
Alcohol consumption0.1560.0760.0852.0450.041
 HDL-CAge0.0670.0110.2536.4040.000
Sex0.2160.0380.2265.6050.000
Alcohol consumption0.1040.0280.1513.7460.000
Body mass index-0.0240.005-0.187-4.5860.000
Diastolic blood pressure0.0050.0020.1142.6620.008
Genotype0.1480.0620.0882.3840.017
 LDL-CBody mass index0.0500.0090.2245.6160.000
Age0.0770.0180.1704.3790.000
Diastolic blood pressure0.0150.0030.2004.8130.000
Alcohol consumption-0.1280.048-0.108-2.670.008
Sex0.2000.0710.1222.8350.005
Cigarette smoking0.0880.0430.092.0530.040
 ApoAIAge0.0580.0070.3368.9230.000
Sex0.1310.0240.2115.4580.000
Alcohol consumption0.0750.0170.1684.3330.000
Diastolic blood pressure0.0030.0010.1132.9400.003
 ApoBBody mass index0.0160.0020.2476.4000.000
Diastolic blood pressure0.0050.0010.2205.6330.000
Age0.0250.0050.1885.0820.000
 ApoAI/ApoBBody mass index-0.0430.007-0.256-6.4910.000
Age0.0450.0130.1333.3840.001

TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B.

Table 5

Correlative factors for serum lipid parameters between males and females in both ethnic groups

Lipid parameterRelative factorUnstandardized coefficientStd. errorStandardized coefficienttP
Bai Ku Yao
 Male
  TCBody mass index0.1300.0270.2674.8690.000
Age0.1050.0410.1392.5390.012
  TGBody mass index0.1280.0360.1973.5160.001
  HDL-CAge0.0640.0180.2043.5630.000
Body mass index-0.0310.011-0.155-2.8700.004
Alcohol comsumption0.1170.0270.2494.3250.000
  LDL-CBody mass index0.1110.0220.2765.0220.000
  ApoAIAge0.0470.0140.1853.2810.001
Alcohol comsumption0.1170.0220.3045.4050.000
  ApoBBody mass index0.0320.0060.3125.7410.000
  ApoAI/ApoBBody mass index-0.0900.023-0.219-3.9470.000
Pulse pressure0.0090.0040.1132.0440.042
Alcohol comsumption0.2230.0540.2304.1070.000
 Female
  TCBody mass index0.0400.0180.1242.2820.023
Systolic blood pressure0.0090.0030.1873.4350.001
  TGAlcohol comsumption0.2970.0700.2314.2610.000
  HDL-CAge0.0450.0130.1833.3400.001
  LDL-CBody mass index0.0320.0140.1262.3270.021
Age0.0500.0250.1192.0340.043
Systolic blood pressure0.0060.0020.1612.7310.007
  ApoAIAge0.0380.0090.2173.9880.000
  ApoBBody mass index0.0100.0040.1272.3380.020
Systolic blood pressure0.0020.0010.2023.7160.000
Han Chinese
 Male
  TCDiastolic blood pressure0.0300.0050.3195.7360.000
Body mass index0.0460.0140.1743.2590.001
Age0.0930.0310.1562.9960.003
  TGBody mass index0.1030.0200.2935.2230.000
Diastolic blood pressure0.0160.0070.1272.2300.026
Alcohol comsumption0.1920.0870.1162.1990.029
  HDL-CAge0.0460.0140.1873.1980.002
Body mass index-0.0320.006-0.295-5.4710.000
Alcohol comsumption0.1050.0270.2023.8820.000
Systolic blood pressure0.0050.0020.1762.9470.003
Genotype0.1920.0840.1172.2770.023
  LDL-CDiastolic blood pressure0.0170.0040.2474.3510.000
Body mass index0.0390.0110.1953.4400.001
  ApoAIAge0.0460.0090.2885.1790.000
Alcohol comsumption0.0750.0170.2204.4480.000
Systolic blood pressure0.0040.0010.2093.6820.000
Body mass index-0.0110.004-0.156-3.0300.003
Genotype0.1280.0520.1202.4440.015
  ApoBDiastolic blood pressure0.0060.0010.2795.1540.000
Body mass index0.0170.0030.2785.1410.000
  ApoAI/ApoBBody mass index-0.0470.009-0.289-5.3780.000
Pulse pressure0.0090.0030.1572.8130.005
Age0.0560.0210.1532.7000.007
 Female
  TCDiastolic blood pressure0.0250.0060.2344.2670.000
Body mass index0.0560.0190.1683.0180.003
Age0.1150.0320.1953.6230.000
  TGDiastolic blood pressure0.0240.0060.2254.1580.000
  HDL-CAge0.0710.0150.2634.9060.000
  LDL-CDiastolic blood pressure0.0150.0050.1783.2630.001
Body mass index0.0620.0140.2394.3100.000
Age0.0850.0250.1853.4430.001
  ApoAIAge0.0670.0090.3737.2530.000
Alcohol comsumption0.1060.0520.1052.0420.042
  ApoBDiastolic blood pressure0.0040.0010.2003.7550.000
Body mass index0.0160.0040.2234.1300.000
Age0.0270.0070.2194.1600.000
Genotype-0.0750.037-0.099-2.0360.043
  ApoAI/ApoBBody mass index-0.0320.010-0.181-3.3480.001
Genotype0.2490.1010.1332.4570.015

TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B.

Correlative factors for serum lipid parameters between Bai Ku Yao and Han Chinese TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B. Correlative factors for serum lipid parameters between males and females in both ethnic groups TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B.

Discussion

We showed that the levels of serum TC, HDL-C, LDL-C and ApoAI were lower in Bai Ku Yao than in Han Chinese. There was no significant difference in the serum levels of TG, ApoB and the ratio of ApoAI to ApoB between the two ethnic groups. It is well known that dyslipidemia is a multifactorial origin, including environmental factors such as demographics, diet, alcohol consumption, cigarette smoking, obesity, exercise, hypertension; genetic factors such as variants in genes coding for proteins; and their interactions [7-13]. Bai Ku Yao is a special and isolated subgroup of the Yao minority in China. Their dietary habits and lifestyle are very special. In addition, strict intra-ethnic marriages have been performed in this ethnic subgroup from time immemorial. Therefore, we believe that some hereditary characteristics and genotypes of lipid metabolism-related genes in this population may be different from those in Han Chinese [9-11]. The frequency spectrum of E670G mutation varied significantly among different races/ethnicities. For example, the frequency of G allele is rare in whites but present in approximately 24.8% of blacks [45]. Kotowski et al. [37] also reported that the minor-allele frequency (670G) in the Dallas Heart Study (DHS) was 3.6% in whites, 4.2% in Hispanics, and 26.0% in blacks. The frequency of the G allele in patients selected from Universitätsklinikum Hamburg-Eppendorf Martinistrasse, Hamburg, Germany was 5% (AA 458, AG 45, GG 3) [39] which lies between that observed in the TexGen population, 4.4% (AA 291, AG 28, GG 0) and that reported for the Lipoprotein Coronary Atherosclerosis Study (LCAS), 7.4% (AA 324, AG 41, GG 7) by Chen et al. [38] in their original study. There was no statistical significant difference in the frequency of the G allele in patients with LDL-C below the 50th percentile for age and sex, 4.4% (AA 93, AG 9, GG 0), those with LDL-C between the 50th and 95th percentiles, 6.4% (AA 160, AG 20, GG 1) and those with LDL-C above the 95th percentile, 6.4% (AA 205, AG 26, GG 2) [39]. The 670G carrier in Chinese Taiwanese was identified less frequently in patients with CAD than in controls (9.9% vs. 11.9%), but the difference was not significant in a multivariable logistic regression analysis [41]. Two previous studies, however, showed that the G allele frequency, 3.4% in healthy U.K. men and patients with clinically defined definite familial hypercholesterolaemia was not associated with any significant effects on plasma lipid levels or CAD risk [43], and 6.0% in Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) was no significant relationships with baseline LDL-C, response to pravastatin, or vascular disease risk being observed [44]. In the present study, we showed that the frequency of G allele of E670G polymorphism in the PCSK9 gene was lower in Bai Ku Yao (2.00%) than in Han Chinese (4.80%). The frequency of AG/GG genotype was also lower in Bai Ku Yao than in Han. There was also significant difference in the genotypic and allelic frequencies between normal and high LDL-C subgroups in Bai Ku Yao; and between normal and low HDL-C, between normal and low ApoAI, or between normal and low ApoAI/ApoB ratio subgroups in Han. These results indicate that the prevalence of the G allele variation of E670G in the PCSK9 gene may have an ethnic specificity. The association of E670G polymorphism in the PCSK9 gene and serum lipid levels is still controversial in several previous studies from ethnically diverse populations. Chen et al. [38] have reported that haplotype structure analysis identified E670G as the determinant variant among a black population, exerting a dose effect (GG > EG > EE) and accounting for 3.5% of plasma LDL-C variability (F = 14.6, P < 0.001). Plasma TC, ApoB, and lipoprotein (a) levels were also associated with the E670G variant. Distributions of the E670G genotypes in an independent normolipidemic and the hyperlipidemic subjects in the LCAS population were significantly different (F = 7.2, P = 0.027). Evans and Beil [39] found that the PCSK9 E670G polymorphism in a European population was associated with increased LDL-C in men but not in women. Norata et al. [40] also showed that the 670G carriers were associated with increased plasma TC, LDL-C, and ApoB levels in the general population. The intima media thickness (IMT) was significantly increased in 670G carriers compared to individuals homozygous for the A allele. The presence of the 670G allele was also significantly associated with a greater progression of IMT compared to 670AA subjects. Contradictory to these previous results, Hsu et al. [41] showed a significantly lower level of LDL-C in 670G carriers in Chinese Taiwanese than in non-carriers (2.78 ± 0.82 mmol/L vs. 3.02 ± 0.85 mmol/L; P = 0.029) among 614 unrelated controls, after adjusting for age, gender, smoking, hypertension, diabetes mellitus, BMI, and use of lipid-lowering agents. However, the association between the E670G polymorphism in the PCSK9 gene and plasma LDL-C levels was not confirmed in other studies [37,43-45]. In the present study, we showed that the G allele carriers in Han but not in Bai Ku Yao had higher serum HDL-C levels and the ratio of ApoAI to ApoB than the G allele noncarriers. When serum lipid parameters in Han were analyzed according to sex, the G allele carriers had higher serum HDL-C and ApoAI levels than the G allele noncarriers in males, whereas the G allele carriers had lower serum ApoB levels and higher the ratio of ApoAI to ApoB than the G allele noncarriers in females. Multiple linear regression analysis showed that the levels of serum HDL-C and ApoAI in Han were correlated with genotypes in males, and the levels of ApoB and the ratio of ApoAI to ApoB were associated with genotypes in females. Although we showed that the levels of serum LDL-C were slightly higher in the subjects with AG/GG genotype than those with AA genotype, the difference did not reach statistical significance. These results suggest that the PCSK9 E670G polymorphism is mainly associated with some serum lipid parameters in the Han population. The reason for this discrepancy is most likely due to racial and ethnic differences among these studies. The study sample of Evans and Beil was men of European origin, the majority (84%) of Chen's sample was American whites, and the sample of Huang et al. [45] was restricted to blacks [124/1750 (7%), because only 3 participants of 1828 whites were found to have this PCSK9 genetic variant. In contrast, our results regarding the E670G polymorphism are restricted to two Chinese populations, Han and Bai Ku Yao. Our study sample is also not different from that of Hsu et al. [41], which included 202 CAD patients and 614 unrelated controls (Chinese Taiwanese). It is well known that dietary patterns, like the Mediterranean diet, are strongly related with blood lipids levels, as well as with the prevalence and the management of dyslipidemia [50]. We slao showed that serum lipid parameters were correlated with age, sex, alcohol consumption, cigarette smoking, BMI, and blood pressure in this study. These data suggest that the environmental factors also play an important role in determining serum lipid levels in our populations [12,13]. The diet and lifestyle were different between the two ethnic groups. Corn was the staple food and rice, soy, buckwheat, sweet potato, and pumpkin products were the subsidiary foods in Bai Ku Yao. Approximately 90% of the beverages were corn wine and rum. The alcohol content is about 15% (v/v). They are also accustomed to drink hempseed soup and eat hempseed products. In contrast, rice was the staple food and corn, broomcorn, potato, and taro products were the subsidiary foods in Han. About 90% of the beverage was rice wine. The content of alcohol is about 30% (v/v). The staple and subsidiary foods are more favorable for serum lipid profiles in Bai Ku Yao than in Han. Corn contains abundant dietary fiber and plant protein [51]. Consumption of dietary fiber, specifically the soluble type, such as pectins and guar gum can decrease serum TC levels [52,53]. Levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) and the LDL/HDL ratio in subjects with moderate hypercholesterolemia were significantly reduced during a mixture of dietary fiber (guar gum, pectin, soy, pea, corn bran) treatment. The mean percentage reductions from baseline after 51 weeks of treatment were approximately 5% for TC, 9% for LDL-C, and 11% for the LDL/HDL ratio. There were no significant effects on the levels of either triglycerides or high-density lipoprotein cholesterol (HDL-C) [53]. Plant protein might promote the transportation and excretion of free cholesterol. Dietary soy protein has well-documented beneficial effects on serum lipid concentrations [54,55]. Soy protein intake is effective in reducing TC by 9.3%, LDL-C by 12.9%, and TG by 10.5% and in increasing HDL-C by 2.4%. Furthermore, the changes in serum TC and LDL-C concentrations were directly related to the initial serum TC concentration [54]. A meta-analyse including 10 studies showed that feeding daily 36 g soy protein with 52 mg soy-associated isoflavones on average decreased LDL-C by -0.17 ± 0.04 mmol/L and increased HDL-C by 0.03 ± 0.01 mmol/L [55]. Buckwheat protein product has a potent hypocholesterolemic activity [56,57]. Son et al. [57] found that plasma lipid profiles in rats differed significantly according to grain combination. The levels of TG in the adlay, buckwheat and waxy barley groups were significantly lower than those in the white rice group. The buckwheat and waxy barley groups showed lower levels of TC and LDL-C, and higher HDL-C than the white rice group. Ingestion of 4 g/day caiapo (the extract of the white-skinned sweet potato Ipomoea batatas) for 6 weeks has been found to reduce plasma TC, LDL-C levels in type 2 diabetic patients previously treated by diet alone [58]. Replacing two thirds of staple food with yam (Dioscorea alata) for 30 days in healthy postmenopausal women can significantly decreased plasma cholesterol concentration by 5.9%, prolonged the lag time of LDL lipoprotein oxidation by 5.8%, and decreased urinary isoprostane levels by 42% [59]. Adaramoye et al. [60] reported that supplemented diets containing 3% and 6% telfairia occidentalis (fluted pumpkin) in rats decreased plasma and postmitochondrial supernatant fraction (PMF) cholesterol levels by 20% and 30% and by 30% and 45%, respectively; decreased the cholesterol-induced increase in plasma and PMF LDL-C levels by 24% and 48% and by 28% and 52%, respectively; and decreased plasma and PMF lipid peroxidation by 24% and 20% and by 42% and 21%, respectively. Dietary hempseed is a rich source of polyunsaturated fatty acids (PUFAs). Hempseed-supplemented diet in animals displayed elevated plasma levels of PUFAs and a prominent enhancement in gamma-linolenic acid levels. When hempseed is added to a cholesterol-enriched diet, cholesterol-induced platelet aggregation returns to control levels [61,62]. This normalization may be partly due to increased levels of plasma gamma-linolenic acid [61]. In addition, several experimental and clinical studies have demonstrated that dietary hempseed or hempseed oil can decrease TC, TG and LDL-C levels [63-65], inhibit lipid peroxidation [66], and reduce atherogenic index [67].

Conclusion

The present study shows that the frequency of G allele of E670G polymorphism in the PCSK9 gene was lower in Bai Ku Yao than in Han. There was also significant difference in the genotypic and allelic frequencies between normal and high LDL-C subgroups in Bai Ku Yao; and between normal and low HDL-C, between normal and low ApoAI, or between normal and low ApoAI/ApoB ratio subgroups in Han. The G allele carriers in Han had higher serum HDL-C and ApoAI levels than the G allele noncarriers in males, whereas the G allele carriers had lower serum ApoB levels and higher the ratio of ApoAI to ApoB than the G allele noncarriers in females. Serum HDL-C and ApoAI levels in Han were correlated with genotypes in males, and serum ApoB levels and the ratio of ApoAI to ApoB were associated with genotypes in females. These results suggest that the PCSK9 E670G polymorphism is mainly associated with some serum lipid parameters in the Han population. The G allele carriers had higher serum HDL-C and ApoAI levels in males, and lower serum ApoB levels and higher the ApoAI/ApoB ratio in females than the G allele noncarriers.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

LHHA participated in the design, undertook genotyping, and helped to draft the manuscript. RXY conceived the study, participated in the design, carried out the epidemiological survey, collected the samples, and drafted the manuscript. LM, XJH, TTY, XLC, DFW, and QL collaborated to the genotyping. SLP and JZW carried out the epidemiological survey, collected the samples, and helped to carry out the genotyping. All authors read and approved the final manuscript.
  61 in total

1.  Comparison of hypertension and its risk factors between the Guangxi Bai Ku Yao and Han populations.

Authors:  Yin Ruixing; Pan Shangling; Li Shuquan; Yang Dezhai; Lin Weixiong; Feng Qiming; Chen Yuming; Huang Yaoheng; Zhou Yijiang; Liao Qinchen
Journal:  Blood Press       Date:  2008       Impact factor: 2.835

2.  The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.

Authors:  Steve Poirier; Gaetan Mayer; Suzanne Benjannet; Eric Bergeron; Jadwiga Marcinkiewicz; Nasha Nassoury; Harald Mayer; Johannes Nimpf; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2007-11-26       Impact factor: 5.157

3.  Cholesterol-induced stimulation of platelet aggregation is prevented by a hempseed-enriched diet.

Authors:  M A Prociuk; A L Edel; M N Richard; N T Gavel; B P Ander; C M C Dupasquier; G N Pierce
Journal:  Can J Physiol Pharmacol       Date:  2008-04       Impact factor: 2.273

4.  Effect of adlay, buckwheat and barley on lipid metabolism and aorta histopathology in rats fed an obesogenic diet.

Authors:  Bo Kyung Son; Jung Yun Kim; Sang Sun Lee
Journal:  Ann Nutr Metab       Date:  2008-06-11       Impact factor: 3.374

5.  Interactions between alcohol intake and the polymorphism of rs708272 on serum high-density lipoprotein cholesterol levels in the Guangxi Hei Yi Zhuang population.

Authors:  Yijiang Zhou; Ruixing Yin; Yaju Deng; Yiyang Li; Jinzhen Wu
Journal:  Alcohol       Date:  2008-11       Impact factor: 2.405

6.  Molecular population genetics of PCSK9: a signature of recent positive selection.

Authors:  Keyue Ding; Iftikhar J Kullo
Journal:  Pharmacogenet Genomics       Date:  2008-03       Impact factor: 2.089

7.  Hyperlipidaemia and its risk factors in the Guangxi Bai Ku Yao and Han populations.

Authors:  Yin Ruixing; Yang Dezhai; Li Shuquan; Chen Yuming; Yang Hanjun; Feng Qiming; Pan Shangling; Lin Weixiong; Tan Jing; Li Yiyang
Journal:  Public Health Nutr       Date:  2008-07-23       Impact factor: 4.022

8.  Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.

Authors:  Eliana Polisecki; Inga Peter; Michele Robertson; Alex D McMahon; Ian Ford; Christopher Packard; James Shepherd; J Wouter Jukema; Gerard J Blauw; Rudi G J Westendorp; Anton J M de Craen; Stella Trompet; Brendan M Buckley; Michael B Murphy; Jose M Ordovas; Ernst J Schaefer
Journal:  Atherosclerosis       Date:  2008-02-08       Impact factor: 5.162

9.  The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan.

Authors:  Lung-An Hsu; Ming-Sheng Teng; Yu-Lin Ko; Chi-Jen Chang; Semon Wu; Chun-Li Wang; Chiao-Feng Hu
Journal:  Clin Chem Lab Med       Date:  2009       Impact factor: 3.694

10.  Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study.

Authors:  Chiang-Ching Huang; Myriam Fornage; Donald M Lloyd-Jones; Gina S Wei; Eric Boerwinkle; Kiang Liu
Journal:  Circ Cardiovasc Genet       Date:  2009-06-10
View more
  22 in total

1.  Combined PCSK9 and APOE polymorphisms are genetic risk factors associated with elevated plasma lipid levels in a Thai population.

Authors:  Nutjaree Jeenduang; Sureerut Porntadavity; Smith Wanmasae
Journal:  Lipids       Date:  2015-04-22       Impact factor: 1.880

2.  Association of BDNF rs11030104 SNP and serum lipid levels in two Chinese ethnic groups.

Authors:  Ling Pan; Man-Qiu Mo; Liu Miao; Qing-Hui Zhang; Shuo Yang; Hui Gao; Feng Huang; Shang-Ling Pan; Rui-Xing Yin
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

3.  Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians.

Authors:  Ching-Wei Tsai; Kari E North; Adrienne Tin; Karin Haack; Nora Franceschini; V Saroja Voruganti; Sandy Laston; Ying Zhang; Lyle G Best; Jean W MacCluer; Terri H Beaty; Ana Navas-Acien; W H Linda Kao; Barbara V Howard
Journal:  J Clin Endocrinol Metab       Date:  2014-11-20       Impact factor: 5.958

Review 4.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.

Authors:  Nicola Ferri; Massimiliano Ruscica
Journal:  Endocrine       Date:  2016-04-01       Impact factor: 3.633

5.  Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort.

Authors:  Afef Slimani; Yahia Harira; Imen Trabelsi; Walid Jomaa; Faouzi Maatouk; Khaldoun Ben Hamda; Mohamed Naceur Slimane
Journal:  J Mol Neurosci       Date:  2014-03-06       Impact factor: 3.444

6.  Association of the apolipoprotein M gene polymorphisms and serum lipid levels.

Authors:  Lynn Htet Htet Aung; Rui-Xing Yin; Dong-Feng Wu; Ting-Ting Yan; Qing Li; Jin-Zhen Wu; Wei-Xiong Lin; Cheng-Wu Liu; Shang-Ling Pan
Journal:  Mol Biol Rep       Date:  2012-10-21       Impact factor: 2.316

7.  APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema.

Authors:  Kristin M Burkart; Ani Manichaikul; Jemma B Wilk; Firas S Ahmed; Gregory L Burke; Paul Enright; Nadia N Hansel; Demondes Haynes; Susan R Heckbert; Eric A Hoffman; Joel D Kaufman; Jun Kurai; Laura Loehr; Stephanie J London; Yang Meng; George T O'Connor; Elizabeth Oelsner; Marcy Petrini; Tess D Pottinger; Charles A Powell; Susan Redline; Jerome I Rotter; Lewis J Smith; María Soler Artigas; Martin D Tobin; Michael Y Tsai; Karol Watson; Wendy White; Taylor R Young; Stephen S Rich; R Graham Barr
Journal:  Eur Respir J       Date:  2013-07-30       Impact factor: 16.671

Review 8.  Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Anwar Santoso; Yulianto Yulianto; Hendra Simarmata; Abhirama Nofandra Putra; Erlin Listiyaningsih
Journal:  Int J Angiol       Date:  2021-02-18

9.  Several genetic polymorphisms interact with overweight/obesity to influence serum lipid levels.

Authors:  Rui-Xing Yin; Dong-Feng Wu; Lin Miao; Lynn Htet Htet Aung; Xiao-Li Cao; Ting-Ting Yan; Xing-Jiang Long; Wan-Ying Liu; Lin Zhang; Meng Li
Journal:  Cardiovasc Diabetol       Date:  2012-10-08       Impact factor: 9.951

10.  Proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism interacts with alcohol consumption to modulate serum lipid levels.

Authors:  Lynn Htet Htet Aung; Rui-Xing Yin; Dong-Feng Wu; Xiao-Li Cao; Xi-Jiang Hu; Lin Miao
Journal:  Int J Med Sci       Date:  2012-12-30       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.